Share Twitter LinkedIn Facebook Email Joan Schiller, MD, shares her thoughts regarding the results of Keynote 42 presented at the 2018 Annual Meeting and how it might impact patient selection. Advertisement
ASCO 2025: Lung Cancer Immunotherapy Breakthroughs from the Immuno-Oncology Symposium Lung Cancer Treatment 4 Mins Read